KR20170021139A - Composition comprising western and oriental medicine for treatment of canine parvovirus infection - Google Patents

Abstract

The present invention relates to a composition for treating canine parvovirus infection which simultaneously comprises western medicine containing chloramphenicol, sulfamethoxazole and trimethoprim and oriental medicine containing pyungwi-san and hyangsapyeongwi-san. The composition according to the present invention has high antiviral and antimicrobial activities, enhances the rate of treating the canine parvovirus infection by improving digestive power of dogs, and remarkably lowers the recurrence rate of diseases.

Description

[0001] The present invention relates to a composition for treating canine parvovirus infection,

The present invention relates to a composition for treating canine parvovirus infection, and more particularly, to a composition for treating canine parvovirus infection, which comprises a combination of chloramphenicol, sulfamethoxazole and trimethoprim and a herbal preparation containing pyruvic acid and pyruvic acid, A composition for treating canine parvovirus infection in which the rate of treatment for viral infection is drastically improved, and a method for treating canine parvovirus infection using the same.

It is an infectious disease caused by dog parvovirus. In Korea, it was first observed in Gyeonggi province in the 1980s and then it occurred nationwide. Clinically and pathologically, it can be divided into two major types, dog type and enteritis type, which can be seen in dogs of 3 to 8 weeks old, which appear in heart type and post - weaning dogs. Symptoms of gastroenteritis include severe vomiting, hemorrhagic diarrhea, marked dehydration, leukocytopenia as the main symptoms and death. Clinical symptoms and pathologic findings are similar to those of Feline panleukopenia (FPL), and treatment for this is known to be effective for early supply of water. In the heart type, it is characterized by non-pyogenic carditis mainly in the left ventricle, and generally progresses acutely, resulting in high mortality and poor prognosis.

The cause of this disease, dog parvovirus, is classified as a parvovirus belonging to parvovirus, and hosts canine animals. One of the viruses that is the smallest among viruses, nucleic acids have short-chain DNA and proliferate well in cell division. It is not inactivated in external environment and shows strong resistance to various disinfectants.

The specific symptoms are severe after 5 days of oral infection. When susceptible dogs are exposed to virus, 100% of dogs are infected, about 75% are infectious, and 25% are having high clinical symptoms. Symptoms are diarrhea at 24-48 hours after the onset of vomiting, early onset, no appetite, loss of appetite and vomiting, and diarrhea with dehydration, weight loss, hydropsy, and blood is observed when continued. Antibodies in serum can be measured 5 days after oral infection and peak at 7-8 days.

The method to prevent dog parvovirus infection is the best way to prevent it through attenuated dog parvovirus vaccination. In the case of intestinal salt type, it is used in case of mild case, Plasma and fluid therapy may be effective when inoculated with an elevated serum antigen within 4 days of infection, and it is known to use antibiotics to prevent corticosteroids or secondary bacteria. Although chlorine, formalin and some drugs are known to be effective at the time of infection, there is no special treatment yet. Korean Patent No. 10-0200324 (a recombinant baculovirus using 5 parvoviruses, a method for producing VP2 recombinant protein using the same, and a canine parvovirus infection vaccine using the recombinant protein) as a composition for preventing canine parvovirus Korean Patent No. 10-0563197 (VP2 recombinant protein comprising a canine parvovirus neutralizing antigenic determinant and a vaccine composition comprising the same) as a composition for prevention and treatment of canine parvovirus, Korean Patent Laid-Open Publication No. 10 -2011-0137743 (a parvovirus high-affinity capsid protein and a feed composition containing the same) for the prevention and treatment of canine parvovirus are known, but these ingredients have a disadvantage that they are difficult to manufacture.

Meanwhile, various antibiotics and antibacterial agents capable of improving dog parvovirus infection have been developed. However, many of the complex agents having synergistic effect when two active ingredients are mixed have not been developed. Most of the compositions of the present invention do not have much research on the combination preparation compositions because they require a long period of time and funds to test the synergistic effect of the active ingredients.

Accordingly, the applicant of the present invention has disclosed an improved antiviral and antimicrobial activity by containing chloramphenicol, sulfamethoxazole and trimethoprim in a specific composition ratio in the registered patent No. 10-09366439 (composition for treatment of canine parvovirus infection) Have developed effective compositions for the treatment of viral infections.

However, the composition for treating canine parvovirus infection developed by the present applicant has a high therapeutic effect, but has a problem that the digestive function is poor, the condition recovery of the dog is slow, and the disease recurs again. The simultaneous administration of drugs commonly known as digestive agents did not improve digestive function.

Accordingly, the present inventors have studied a drug that can improve the digestive function without compromising the efficacy of the parvovirus treatment and can help the rapid recovery of the drug, while the herbal medicine containing pyruvic acid and pyruvic acid is used as the above-mentioned chloramphenicol, sulfamethoxazole, The present invention has been completed based on the discovery that, when administered simultaneously with a medicament containing trimethoprim, the digestive function of the dog is improved and the energy recovery rate of the parvovirus infection is greatly improved and the recurrence rate of the disease is remarkably reduced.

It is an object of the present invention to provide a medicament containing chloramphenicol, sulfamethoxazole and trimethoprim; Also disclosed is a composition for the treatment of canine parvovirus infection, which comprises both oriental herbal medicine containing pyruvic acid and oriental pyruvic acid and is excellent in the improvement effect of canine parvovirus infection and prevents recurrence of disease.

Another object of the present invention is to provide a method for treating canine parvovirus infection comprising administering the composition.

According to one aspect of the present invention there is provided a pharmaceutical composition comprising: a preparation comprising chloramphenicol, sulfamethoxazole and trimethoprim; And herbal medicine containing pyruvic acid and pyruvic acid, and a composition for treating canine parvovirus infection.

In the present invention, the chloramphenicol, sulfamethoxazole and trimethoprim may be contained in a weight ratio of 2: 5: 4 to 6: 0.5 to 1.5.

In the present invention, the pale acid and the pale peach acid may be contained in a weight ratio of 1: 1.

The pyruvic acid in the present invention contains Creation, Dermis, Fragrance, Fir, Wrinkle, Clove, Cod, Lycopersicum, Licorice and Ginger, and the pyruvic acid contains Agar, Dermatophagoides, Licorice, Ginger and Jujube.

In the present invention, the composition may be a pharmaceutical composition for oral administration.

According to another aspect of the present invention, there is provided a method of treating canine parvovirus infection comprising administering the composition.

The composition according to the present invention simultaneously contains both a herbal composition containing chloramphenicol, sulfamethoxazole and trimethoprim and a herbal medicine containing pyrazic acid and pyruvic acid and having antiviral and antimicrobial activity, It has the effect of improving the digestive power of the dog with high treating ability of the infectious layer, greatly improving the treatment speed and remarkably lowering the recurrence rate of the disease.

Therefore, the composition is effective for the treatment of canine parvovirus infection, and thus can be usefully used for the preparation of a therapeutic agent for parvovirus infection in canines.

Moreover, it can be seen that the therapeutic effect of 90% or more is exhibited by the present invention in which the conventional treatment effect remained at 70%.

Brief Description of the Drawings Fig. 1 is a report showing progress of treatment when a herbal composition containing herbal and herbal remedies according to an embodiment of the present invention is applied to canine parvovirus infection.
2 is a report showing the effect of the invention invented by the present inventor.
FIG. 3 is a business registration card of a doctor who provided the results of the experiment on the present invention.

Hereinafter, the configuration of the present invention will be described in more detail.

In one embodiment, the present invention provides a method of treating a patient suffering from a condition selected from the group consisting of: a patient comprising chloramphenicol, sulfamethoxazole and trimethoprim; And herbal medicine containing pyruvic acid and pyruvic acid, and a composition for treating canine parvovirus infection.

The composition of the present invention simultaneously contains a herbal preparation containing chloramphenicol, sulfamethoxazole and trimethoprim and a herbal medicine containing herbal acid and pyruvic acid, thereby enhancing digestive power of dogs with high antiviral and antimicrobial activity By increasing the rate of treatment of the disease and preventing the recurrence of the disease, it exerts an excellent effect in the treatment of dog parvovirus infection.

In the present invention, canine parvovirus infection is an infectious disease caused by dog parvovirus. Especially, it is highly infectious to mothers. Major symptoms are vomiting, diarrhea. Diarrhea, hyperthermia and dehydration, and if they are not properly calibrated, it is a fatal disease that causes destruction of the immune system balance due to intestinal injury and bone marrow injury, eventually leading to death.

The chloramphenicol contained in the composition of the present invention is a kind of antibiotics produced by actinomycetes Streptomyces venezuela and exhibits antimicrobial activity by inhibiting the ability of microorganisms to synthesize specific active proteins, It is known to be applicable.

The sulfamethoxazole contained in the composition of the present invention is a kind of sulfamide-based antimicrobial agent and is a compound having a chemical name of 4-amino-N- (5-methylisoxazol-3-yl) -benzenesulfonamide 5-methylisoxazol-3-yl) -benzenesulfonamide ". Sulfamethoxazole reversibly inhibits bacterial folate synthesis, exhibits bacteriostatic activity, and is known to be used in the treatment of various bacterial infections.

Trimethoprim, another antimicrobial agent included in the composition of the present invention, is known as a substance that has an antimicrobial action by inhibiting folate synthesis of bacteria such as sulfamethoxazole, and its chemical name is "5- (3,4,5-tri (3,4,5-trimethoxybenzyl) pyrimidine-2,4-diamine ".

In the present invention, the respective compounds of chloramphenicol, sulfamethoxazole and trimethoprim, which are compounds, can be directly synthesized through a known synthesis method or commercially available ones can be used. The compounds of the present invention may also be used in the form of pharmaceutically acceptable salts or derivatives of the compounds, without loss of effective antiviral activity, and the salts or derivatives of the compounds may be prepared by methods known in the art ≪ / RTI >

The term "pharmaceutically acceptable salt " of the compound in the present invention means salts derived from pharmacologically or physiologically acceptable inorganic acids, organic acids and bases. Examples of suitable acids include hydrochloric acid, hydrobromic acid, sulfuric acid, But are not limited to, perchloric, fumaric, maleic, phosphoric, glycolic, lactic, salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric, methanesulfonic, formic, benzoic, malonic, naphthalene- And salts derived from suitable bases may include, but are not limited to, alkali metals such as sodium, alkaline earth metals such as magnesium, ammonium, and the like.

The composition of the present invention is characterized in that it contains antibiotic chloramphenicol, antimicrobial agents sulfamethoxazole and trimethoprim in the form of a combination, and has enhanced antiviral activity. In other words, the composition of the present invention exhibits enhanced antiviral and antimicrobial activity against canine parvovirus and bacterial pathogens, and has an excellent effect for the treatment and prevention of canine parvovirus infection.

In addition, the composition of the present invention can further increase antiviral and antimicrobial activity against parvovirus and bacterial pathogens by adjusting the mixing ratio of the above components. It is preferable that each of the above-mentioned components included in the composition of the present invention is contained in a weight ratio of chloramphenicol, sulfamethoxazole and trimethoprim in a weight ratio of 2: 5: 4 to 6: 0.5 to 1.5 based on the dry powder weight, Most preferably in a weight ratio of 3.2: 5: 1. If the composition of the present invention exceeds the appropriate mixing ratio range as described above, it may not have enhanced antiviral and antimicrobial activity, or it may cause adverse effects such as toxicity to internal organs, especially digestive organs due to excessive drug use . In addition, the composition for treating canine parvovirus infection of the present invention may further comprise known antimicrobial agents, antibiotics and anti-inflammatory agents.

The composition of the present invention is characterized in that it contains a herbal medicine containing pusan acid and pumice pyruvic acid in addition to the above-mentioned medicament. Herbal medicine (herbal medicine), unlike the single compound, which is the main ingredient that determines the efficacy of the drug in addition to various sub-ingredients contain the pharmacological effects can be complex. Thus, especially when taken simultaneously with the medicament, various biomechanical mechanisms may be involved, and other additional effects besides specific pharmacological effects may be obtained.

The pyruvic acid is a prescription used to treat diseases of digestive system diseases, and is recorded in Donguibogam, and is known to be used for symptom treatment such as anorexia, abdominal pain, vomiting, and diarrhea. It is known that pyruvic acid is used for symptoms such as acute gastritis, duodenal ulcer, gastric ulcer and diarrhea caused by lowered digestive system function.

Pyroxin and pyruvic acid are drugs to prescribe when there is digestive disturbance. They help digestion and remove the gas by warming the living body of the livestock, especially the stomach.

The pyruvic acid may contain Creation, Lilac, Dermis, Ginger, Jujube and Licorice. The composition ratio of each component can be used in a composition known in the art. For example, it can be used in a composition ratio of Creation 4.0: Grass 3.0: Derm 3.0: Ginger 2.0: Jujube 2.0: Licorice 1.0.

In addition, the perilla pyruvic acid may contain Creation, Dermis, Fragrance, Garlic, Garlic, Garlic, Cod, Moss, Licorice and Ginger. The composition ratio of each component can be a composition known in the art, for example, Creation 4.0: Dermis 2.0: Fructus 2.0: Starch 1.5: Welsh 1.5: Grass 1.5: Sine 1.5: .

The characteristics of the components contained in the pyeongsan and the equilibrium acid are as follows.

It is a medicinal herb made from Atractylodes japonica ( KOIDZ. Et. KITAGAWA ), A. lancea DC. , And A. chinensis KOIDZ , which belong to the family Asteraceae. The main components are Atractylol, Hinesol, and β-Eudesmol. The flavor of the medicine is a little bit too warm and the fever is warm. Efficacy improves digestive disturbances and gastrointestinal weakness, especially edema of the digestive tract mucosa, to improve area and vomiting.

The dermis refers to the bark or trunk of the ash tree (Fraxinus rhynchophylla Hance). The dermis has the efficacy of lowering fever and drying out the dampness, and it is used for dysentery, fever, dandruff, ocular hyperemia, pain, seawater and asthma. The pharmacological action was reported as inflammation, analgesia, excretion of uric acid, genitalia and genitalia.

It is the bark or root bark of Magnolia ( officinalis, obovata, officinalis var. Biloba ). Glutinous antimicrobial action to improve the bowel and abdominal pain is a gyeonggyeong.

Licorice is a perennial herbaceous perennial plant with rosemary roots, and its scientific name is Glycyrrhiza uralensis . The pharmacological effects of licorice are effective against detoxification, hepatitis, urticaria, dermatitis, and eczema. Jinhae, geomung, muscle relaxation, diuretic, anti-inflammatory action and suppress peptic ulcer.

Ginger refers to the fresh roots and stems of Zingiber officinale. Ginger is effective in preventing colds, diarrhea, vomiting and gastritis.

Jujube is the fruit of the jujube tree. Jujube mainly contains sugar, mucus, maltic acid, and tartaric acid. Seeds contain Betuline, Betulic acid, and fat, and are widely used as medicines for diuretic, calmness, and dryness in one room.

The fragrant herb is a perennial herbaceous plant belonging to the genus Zygosacantha. Its scientific name is Cyperus rotundus L.. It grows in the sandy beaches or on the waterfront. It grows to the side, the base of the stem grows thicker, and the stem of the root grows at the end of the root. The roots of roots at the root end contain essential oils and fatty oils. They are used for headache, abdominal pain, and menstrual irregularities in one room, and also as eukaryotic agents for pulmonary tuberculosis in the private sector.

Sign represents a medicinal product made from fruit of Amanum villosum LOUR. It is a perennial herbaceous plant belonging to the ginger family. Signs are effective for dyspepsia and vomiting due to gastrointestinal dysfunction.

Gwak is a medicinal substance made from the ground of Agastache rugosa (Fisc.r et Mey.) Kuntze). Gwak is used to treat abdominal cavity, appetite loss, nausea, vomiting and diarrhea. It shows antibacterial activity against Escherichia coli, Disease, and Pneumococcus and has effects on cold, vomiting, diarrhea, bad breath, have.

It is the roots of Aucklandia lappa Decne. In Korea. It is used for abdominal pain, diarrhea, vomiting and diarrhea caused by abdominal pain. It is effective for chronic inflammation of stomach, stomach cramps, and antibacterial activity.

The oriental herbal medicine of pyeonyangsan and oriental oriental herb medicine can be obtained by using commercially available oriental herbal medicine or can be manufactured by using an extraction method known in the art. The herbal medicine for oriental medicine can be used in all kinds of extraction forms such as hot water extract, fluid extract, distillation extract and freeze-dried powder without limitation, and preferably granules or powder obtained by hot water extraction or distillation extraction and drying, Type extract may be used, and most preferably, those prepared in the form of a dry granular powder prepared according to a high-fat preparation method may be used.

When the herbal medicine is used in the form of dried granule powder, the herbal medicine may be used in an amount of 3 to 10 g, preferably 4 to 6 g, and more preferably 5 g. An adequate level of pharmacological effect can be anticipated without side effects in such a content range. The pyruvic acid and pyruvic acid may be used in a weight ratio of 0.5 to 1.5: 0.5 to 1.5, preferably 1: 1. In this range, the rate of treatment of canine parvovirus infection is further increased and the recurrence rate is decreased.

Since the composition of the present invention shows a therapeutic effect on canine parvovirus infection, it can be applied to canidae, preferably dogs, especially dogs.

In the 'treatment and prevention' of the present invention, 'treatment' means all actions that improve or modify the dog parvovirus infection by administering the composition. By 'administering the composition of the present invention, Or delaying the onset of the disease.

The composition for treating canine parvovirus infection of the present invention may further comprise a pharmaceutically acceptable carrier and may be formulated together with a carrier.

As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not irritate the organism and does not interfere with the biological activity and properties of the administered compound.

The composition of the present invention can be prepared by uniformly and thoroughly contacting a capsule containing the active ingredient of the present invention, i.e., a capsule containing chloramphenicol, sulfamethoxazole and trimethoprim, with or without an excipient, or with an atomized solid carrier, liquid carrier or both And, if necessary, the product can be molded into a desired formulation and used. And as examples of excipients suitable carriers include starch, water, saline, ethanol, glycerol, Ringer's solution and dextrose solution or the like, the literature (Remington`s Pharmaceutical Science, 19 ^th Ed., 1995, Mack Publishing Company, Easton PA), etc. May be formulated into suitable formulations known in the art as disclosed herein. The compound of the present invention may be formulated in an amount of 0.0001 to 99% by weight, preferably 50 to 80% by weight, based on the total weight of the total composition.

In addition, the composition of the present invention can be applied to any formulation containing it as an active ingredient and can be manufactured into oral or parenteral formulations. The pharmaceutical formulations of the present invention may be administered orally, rectally, nasal, topical (including under the ball and tongue), subcutaneous, vaginal or parenteral (intramuscular, subcutaneous And intravenous), or forms suitable for administration by inhalation or insufflation.

Examples of formulations for oral administration comprising the composition of the present invention as an active ingredient include tablets, troches, lozenges, aqueous or oily suspensions, prepared powders or granules, emulsions, hard or soft capsules, syrups or elixirs Can be formulated. A binder such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin, an excipient such as dicalcium phosphate, a disintegrating agent such as corn starch or sweet potato starch, a disintegrant such as magnesium stearate , Calcium stearate, sodium stearyl fumarate or polyethylene glycol wax. In the case of a capsule formulation, in addition to the above-mentioned materials, a liquid carrier such as a fatty oil may be further contained.

Examples of the formulations for parenteral administration containing the composition of the present invention as an active ingredient include injection forms such as subcutaneous injection, intravenous injection or intramuscular injection, suppository injection method, or aerosol agent for inhalation through a respirator . ≪ / RTI > For formulation into injectable formulations, the compositions of the present invention may be formulated as solutions or suspensions in water with stabilizers or buffers in water, and formulated for unitary administration of ampoules or vials. For injection into suppositories, it may be formulated into rectal compositions such as suppositories or enema preservatives, including conventional suppository bases such as cocoa butter or other glycerides. When formulated for spraying, such as an aerosol formulation, a propellant or the like may be formulated with the additive such that the water-dispersed concentrate or wet powder is dispersed.

In another aspect, the present invention relates to a medicament containing the above-mentioned chloramphenicol, sulfamethoxazole and trimethoprim; And a herbal medicine containing pyruvic acid and pyruvic acid; and a method for treating a canine parvovirus infection comprising administering a composition for treating canine parvovirus infection.

The term "administering" as used herein means introducing the pharmaceutical composition of the present invention into an animal by any appropriate method, and the administration route of the composition of the present invention may be administered orally or parenterally in various routes And can be administered in a conventional manner via oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, intranasal, inhalation, ocular or intradermal routes . Preferably, it is orally administered.

The method of treatment of the present invention comprises administering the compound in a pharmaceutically effective amount. The appropriate total daily dose may be determined by the practitioner within the scope of appropriate medical judgment. The specific therapeutically effective amount for a particular animal will depend upon a variety of factors, including the type and extent of the response to be achieved, the specific composition including whether or not other agents are used, the age, weight, general health status, sex and diet, The route of administration and the fraction of the composition, the duration of the treatment, the drugs used or co-used with the specific composition, and the like, well known in the medical arts. Accordingly, the preferable dosage of the compound of the present invention can be determined in view of the above-mentioned matters, and can be appropriately selected by those skilled in the art. However, for the desired effect, the compound of the present invention can be administered in an amount of 0.0001 to 1000 mg / kg, preferably 0.01 to 200 mg / kg, once or several times per day. A preferred dose based on the individual can be administered in an amount of 200 to 3000 mg per day, based on the total weight of the combination, once to three times a day. The administration of the combination composition of the present invention includes not only administering a pharmaceutical composition formulated with a single combination agent, but also separately administering each of the constituent substances after formulation. In the case of dry granular powder for oral administration, herbal medicine may be used in an amount of 3 to 10 g, preferably 4 to 6 g, more preferably 5 g, Lt; / RTI >

In addition, the composition of the present invention can be used alone for treatment and prevention of canine parvovirus infection, or in combination with methods using surgery, hormone therapy, drug therapy and biological response modifiers.

Hereinafter, the configuration and operation of the present invention will be described in more detail with reference to preferred embodiments of the present invention. However, the following examples are provided to aid understanding of the present invention, and the scope of the present invention is not limited to the following examples. The contents not described here are sufficiently technically inferior to those skilled in the art, and a description thereof will be omitted.

Example 1. Evaluation of antiviral activity of a combination drug for treating canine parvovirus infection

In order to evaluate the antiviral activity of the herbal medicine combination preparation and oriental herbal medicine, the components were mixed with the composition shown in Table 1 below, and each drug was prepared, and the antiviral activity against parvovirus was examined. In the case of the medicines, the respective compounds were mixed in a composition ratio shown in Table 1 on a weight basis, and then dissolved in water to prepare a 5% aqueous solution. Herbal medicines were prepared as commercially available granular powdery pseudosilicic acid and mesophilic acid, and then 10% aqueous solution was prepared.

To measure the inhibitory effect on virus proliferation, 2 x 10 ⁴ CRFK cells were added to each well of 96-well plates and cultured for 24 hours. After 24 hours, the culture supernatant of each well was removed and the parvovirus infectious solution was added to each well, and each complex was treated in each well at a concentration of 50 μg / ml media. Herbal remedies were applied to each well at a concentration of 100 μg / ml media. The viability of each drug was measured by the SRB assay [Martin A et al., 1997, Cytotechnology, 11: 49-54] after 72 hours. 100 μl of 10% TCA (trichloroacetic acid) was added to each well, followed by incubation at 4 ° C for 1 hour and washing with distilled water several times. After drying at room temperature, 100 μl of 0.4% (w / v) SRB (sulforhodamine B) solution dissolved in 1% (v / v) acetic acid was added and stained for 30 minutes. The SRB staining solution not bound to the cells was washed several times with 1% (v / v) acetic acid and dried again. To each well, 100 μl of 10 mM Tris solution (pH 10.5) was added to each well to sufficiently dissolve the stain bound to the cells, and the absorbance was measured at 560 nm. Each treatment group was labeled with no virus treatment group (A), only compound treatment group (B), only virus treatment group (C), and treated with virus and compound treatment group (D) (%) ≪ / RTI > The results are shown as the mean value and the standard deviation of the results of three experiments performed under the same conditions.

process Formulation Parvovirus
Proliferation inhibition (%) Drug 1 Composite 1 29.31 + - 2.54 Drug 2 Composite 2 16.1 + 1.24 Drug 3 Composite 3 22.54 + - 8.54 Drug 4 Composite 4 18.21 + - 6.21 Drug 5 Single item 1 15.46 ± 0.24 Drug 6 Single 2 13.19 ± 1.17 Drug 7 Complex 1 + pyeongsan + incense pyeongsan 32.27 + - 5.87 Drug 8 Complex 1 + Pyongyangsan 30.12 + 1.69 Drug 9 Complex 1 + incense pyeongsan 30.82 + - 4.55 Formulation - (chloramphenicol: sulfamethoxazole: trimethoprim)
Composite 1 - (3.2: 5: 1)
* Composite 2 - (1: 5: 1)
Composite 3 - (3.2: 3: 2)
* Composite 4 - (6: 2: 1)
* Single-product 1-chloramphenicol
* Single 2-sulfamethoxazole

As shown in Table 1, the compound composition of the present invention showed almost no cytotoxicity of the compound itself, and showed a difference in antiviral activity depending on the composition ratio of each component. When the ratio of chloramphenicol, sulfamethoxazole and trimethoprim in the complex is in the range of 2: 5: 4 to 6: 0.5 to 1.5, particularly 3.2: 5: 1, by weight, It was confirmed that the antiviral activity was high. In addition, it was confirmed that the antiviral activity was further enhanced when the pesticide 1 and the pyruvic acid were further treated with the combination agent 1.

Example 2. Preparation of preparations for oral administration

<2-1> Manufacture of medicine

A combination oral dosage form for the treatment of dog parvovirus infection was prepared.

Each of the complexes was mixed in powder form in the same manner as the composition ratios of the preparations of Example 1 (Complex 1 to Complex 4, Single 1 and Single 2), and then pharmaceutical excipients were added thereto to prepare tablets according to a conventional preparation method Respectively. The components of each combination agent are shown in Table 2 below.

Chloramphenicol (mg) Sulfamethoxazole (mg) Trimethoprim (mg) Composition ratio Composite 1 125 200 40 3.2: 5: 1 Composite 2 40 200 40 1: 5: 1 Composite 3 125 120 80 3.2: 3: 2 Composite 4 240 80 40 6: 2: 1 Single item 1 200 0 0 - Single 2 0 200 0 -

<2-2> Herbal remedy preparation

A commercially available granular powder and a flavor enhancer preparation were prepared.

<2-3> Preparing the Exfoliating Agent

(A single compound) for comparative experiments with herbal remedies was prepared. 200 mg of pancreatin, 200 mg of diastase, and 100 mg of panfosine were prepared as extinguishing agents.

Example 3 Diarrhea suppression test

The preparation prepared in Example 2 was administered to dogs showing symptoms of vomiting and diarrhea caused by parvovirus three times a day. The herbal medicine pyeongsan acid and herbal pyeongsan acid preparation were administered at a dose of 5g each.

The compound for oral administration prepared in Example 2 was administered to dogs showing symptoms of vomiting and diarrhea three times a day over three times (the administration was started within three days from the day on which diarrhea symptoms were shown, 20 rats were grouped and administered, and average values were calculated for each formulation). On day 2, 3, 5 and 10, diarrhea suppression effect (weak 0 → strong) was shown in Table 3 below.

2 days 3 days 5 days 10 days Medication 1 Composite 1 4.6 5.2 6.9 8.5 Medication 2 Composite 2 2.6 3.0 4.2 5.7 Medication 3 Composite 3 4.1 4.5 5.3 7.2 Medication 4 Composite 4 3.0 3.5 5.0 6.5 Dosage 5 Single item 1 2.1 2.6 2.9 3.1 Medication 6 Single 2 1.7 2.1 2.4 2.7 Medication 7 Complex 1 + pyeongsan + incense pyeongsan 6.5 7.4 8.5 9.7 Medication 8 Complex 1 + Pyongyangsan 5.7 6.8 7.7 9.0 Medication 9 Complex 1 + incense pyeongsan 5.8 6.9 7.8 9.1 Medication 10 Complex 1 + Pancreatin 4.8 5.4 7.0 8.6 Medication 11 Complex 1 + diastase 4.7 5.3 6.9 8.6 Medication 12 Compound 1 + panfurocin 4.6 5.3 6.9 8.5

As shown in Table 3, the combination agent of the present invention had a higher diarrhea inhibiting ability than the single agent, and the weight ratio of chloramphenicol, sulfamethoxazole and trimethoprim in the complex was in the range of 2: 5: 4 to 6: 0.5 to 1.5, : 5: 1 weight ratio (Combination 1), the highest diarrhea inhibitory effect was obtained.

However, in the case of administering only the combination of the medicinal herbs, the digestive power of the dogs was lowered and the gas was introduced into the intestines. In order to alleviate this problem, herbal remedy for herbal medicine (herbal medicine for enhancing digestive power) and common herbal medicine were administered to compare the symptom relief effect.

In addition, it can be confirmed that diarrhea suppressing effect is further enhanced when the herbal medicine herbal medicine pyeongyusan and oriental pyruvic acid are taken together (medicines 7, 8, 9) in addition to the combination agent. In particular, it is confirmed that the treatment effect is significantly improved by improving the diarrhea suppressing effect remarkably on the second and third days. (P <0.05). The results showed that the treatment rate was the fastest (p <0.05). However, in the case of administration of conventional medicaments together with Compound 1 (medication 10, 11, 12), the digestibility was not improved and the treatment rate was not affected.

Example 4. Comparison of recurrence rate and mortality of a disease

With the progress of the experiment of Example 3, the recurrence rate and mortality rate (the number of recurrences among 20 rats per each administration group, the number of dead rats per each experimental group) were shown and expressed as percentiles. The recurrence rate was recurred 10 days after administration and the mortality rate was investigated 20 days after administration.

Recurrence rate (%) Mortality (%) Medication 1 Composite 1 25 20 Medication 2 Composite 2 50 40 Medication 3 Composite 3 30 20 Medication 4 Composite 4 40 30 Dosage 5 Single item 1 60 50 Medication 6 Single 2 70 60 Medication 7 Complex 1 + pyeongsan + incense pyeongsan 5 5 Medication 8 Complex 1 + Pyongyangsan 15 10 Medication 9 Complex 1 + incense pyeongsan 10 10 Medication 10 Complex 1 + Pancreatin 25 20 Medication 11 Complex 1 + diastase 25 20 Medication 12 Compound 1 + panfurocin 30 25

As shown in Table 4, it was confirmed that the mortality rate of the conjugate administration group of the present invention was lower than that of the single agent administration group. In addition, it was confirmed that the recurrence rate and the mortality rate were remarkably lowered when the oriental herbal medicine was administered together with the combination medicine (medication 7, 8, 9). Particularly, when both pyrazic acid and pyrazolium acid were added at the same time, the recurrence rate and mortality of the disease were the best. However, in the case of administration of a combination medication with a combination medication (medication 10, 11, 12), the recurrence rate and mortality of the disease were not significantly reduced. Figure 1 shows the treatment results for some of the 7 groups of medicines (12 rats).

Claims (5)

A juice containing chloramphenicol, sulfamethoxazole and trimethoprim; And oriental herbal medicine containing pyeongsan acid and oriental pyrazic acid; &Lt; / RTI &gt; or a pharmaceutically acceptable salt thereof.
The composition for treating canine parvovirus infection according to claim 1, wherein the chloramphenicol, sulfamethoxazole and trimethoprim are contained in a weight ratio of 2: 5: 4 to 6: 0.5 to 1.5.
2. The composition for treating canine parvovirus infection according to claim 1, wherein the pyruvic acid and the perilla pyruvic acid are contained in a weight ratio of 1: 1.
[Claim 3] The method according to claim 1, wherein the perilla flavor comprises Creation, Dermis, Fragrance, Garlic, Garlic, Garlic, Cod, Moss, Licorice and Ginger,
Wherein the pyruvic acid comprises Agaricus aurans, Dermis, Lilac, Licorice, Ginger and Jujube.
The composition for treating canine parvovirus infection according to claim 1, wherein the composition is a pharmaceutical composition for oral administration.

Images